Roche partnership brings $700M upfront for NRx BTK degrader
Roche partnership expands the clinical and commercial reach of a BTK degrader, with $700M upfront and up to $2.3B in milestones.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.